Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2023 08:30 ET | Source: ABVC BioPharma, Inc.

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
November 17, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
November 14, 2022 18:20 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
November 07, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
November 02, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients

FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
October 05, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia

FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
September 23, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval

FREEMONT, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
September 13, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC Biopharma Announces Letter to Shareholders

FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
September 09, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC BioPharma Selects Additional Vitargus® Phase II Study Site

New Australia Site Confirmed to Participate in the Study FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical...
August 22, 2022 08:30 ET | Source: ABVC BioPharma, Inc.

ABVC Provides Oncology Pipeline Updates

Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right